Research programme: oral cancer therapeutic - Privo Technologies

Drug Profile

Research programme: oral cancer therapeutic - Privo Technologies

Alternative Names: Cisplatin Transmucosal System - Privo Technologies; PRV111

Latest Information Update: 29 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Privo Technologies
  • Class Antineoplastics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Orofacial cancer

Most Recent Events

  • 18 Apr 2018 Privo Technologies plans a phase I/II trial for Squamous cell carcinoma in USA , (NCT03502148)
  • 29 Jul 2016 Preclinical trials in Orofacial cancer in USA (Buccal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top